National Resilience Boosts Contract Manufacturing with $225M Ohio Investment

• National Resilience is investing $225 million into its Ohio facility. The company is also expanding its manufacturing operations in North Carolina.

National Resilience, a technology-focused biomanufacturing company, has announced a significant investment of $225 million into its Ohio facility.

By 2025, it aims to produce more than 200 million units across its network for various types of treatments, including the widely used GLP-1 treatments for diabetes and obesity.

The CDMO was founded in 2020 with more than $800 million in capital. While the company initially emerged with a focus on the U.S. and Canada, by 2023 it had announced plans to build factories in the Saudi Arabia and the United Arab Emirates.

“As a highly experienced team already supporting a leading pharmaceutical company with their GLP-1 products, this expansion further supports Resilience’s mission to ensure adequate biomanufacturing capacity by addressing and overcoming historic manufacturing challenges throughout the industry,” said Rahul Singhvi, Resilience’s chief executive officer.